Article
Activated type 17 helper T cells affect tofacitinib treatment outcomes
2024-04-09
Abstract excerpt
<title>Abstract</title> <p><bold>Background</bold>: The incidence of ulcerative colitis (UC) is on the rise also in Japan. Simultaneously, therapeutic options, including biologics and Janus kinase (JAK) inhibitors, have significantly expanded over the past decade. Although tofacitinib (TOF), one of JAK inhibitors, is a viable option for patients with moderate to severe UC, there is insufficient data to predict re...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- a536a4f8-d626-50a7-a60c-2eefc6b8f94e
- DOI
- 10.21203/rs.3.rs-4130967/v1
